Targeting apoptosis to induce stable mixed hematopoietic chimerism and long-term allograft survival without myelosuppressive conditioning in mice

Blood

Volumn 122, Issue 9, 2013, Pages 1669-1677

  Cippa, Pietro E ^a,b   Gabriel, Sarah S ^a,b   Chen, Jin ^a,b   Bardwell, Philip D ^c   Bushell, Andrew ^d   Guimezanes, Annick ^e   Kraus, Anna K ^a,b   Wekerle, Thomas ^f   Wüthrich, Rudolf P ^a,b   Fehr, Thomas ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ABBOTT LABORATORIES   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CYCLOSPORIN A; ABT-737; BIPHENYL DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; SULFONAMIDE;

ALLOREACTIVE T CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CD8+ T LYMPHOCYTE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENGRAFTMENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPHARMACOLOGY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED HEMATOPOIETIC CHIMERISM; MONOTHERAPY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SKIN GRAFT; SPLEEN CELL; SURVIVAL TIME; TRANSPLANTATION CONDITIONING; UPREGULATION; WHOLE BODY RADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CBA MOUSE; CELL CULTURE; DRUG EFFECTS; HEMATOPOIESIS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION TOLERANCE; DRUG ANTAGONISM; DRUG EFFECT; METHODOLOGY;

ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; CELLS, CULTURED; GRAFT SURVIVAL; HEMATOPOIESIS; IMMUNOSUPPRESSION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; UP-REGULATION;

EID: 84891513443     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-453944     Document Type: Article

References (47)

1. Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int. 2008;21(12):1118-1135.
2. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998;187(12):2037-2044.
3. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol. 2002;14(5):592-600.
4. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med. 2011; 365(14):1359-1360.
5. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358(4):353-361.
6. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med. 2012;4(124): 124ra128.
7. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant. 2006; 6(9):2121-2133.
8. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med. 1999;5(11):1298-1302.
9. Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol. 2003;21:71-105.
10. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood. 2003;101(7):2886-2893.
11. Fehr T, Lucas CL, Kurtz J, et al. A CD8 T cellintrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo. Blood. 2010;115(6): 1280-1287.
12. Ford ML, Koehn BH, Wagener ME, et al. Antigenspecific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med. 2007;204(2):299-309.
13. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 1999;5(11): 1303-1307.
14. Wekerle T, Kurtz J, Sayegh M, et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol. 2001;166(4):2311-2316.
15. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-681.
16. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
17. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: Small molecules with a big impact on cancer therapy. Cell Death Differ. 2009;16(3): 360-367.
18. Carrington EM, Vikstrom IB, Light A, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA. 2010;107(24):10967-10971.
19. Bardwell PD, Gu J, McCarthy D, et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009;182(12):7482-7489.
20. Cippà PE, Kraus AK, Edenhofer I, et al. The BH3- mimetic ABT-737 inhibits allogeneic immune responses. Transpl Int. 2011;24(7):722-732.
21. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12): 1149-1159.
22. Cippà PE, Kraus AK, Lindenmeyer MT, et al. Resistance to ABT-737 in activated T lymphocytes: Molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway. Cell Death Dis. 2012;3:e299.
23. Cippà PE, Kamarashev J, Chen J, et al. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A. Apoptosis. 2013;18(3):315-323.
24. Auphan N, Curnow J, Guimezanes A, et al. The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR-transgenic mice. Eur J Immunol. 1994;24(7):1572-1577.
25. Guimezanes A, Barrett-Wilt GA, Gulden- Thompson P, et al. Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: Distinct characteristics correlated with CD8 dependence. Eur J Immunol. 2001;31(2):421-432.
26. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735-1738.
27. Buferne M, Luton F, Letourneur F, et al. Role of CD3 delta in surface expression of the TCR/CD3 complex and in activation for killing analyzed with a CD3 delta-negative cytotoxic T lymphocyte variant. J Immunol. 1992;148(3):657-664.
28. Sandalova E, Wei CH, Masucci MG, Levitsky V. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci USA. 2004;101(9):3011-3016.
29. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000;6(4):464-469.
30. Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14(4):417-424.
31. Ludwinski MW, Sun J, Hilliard B, et al. Critical roles of Bim in T cell activation and T cellmediated autoimmune inflammation in mice. J Clin Invest. 2009;119(6):1706-1713.
32. Sabbagh L, Pulle G, Liu Y, Tsitsikov EN, Watts TH. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol. 2008;180(12):8093-8101.
33. Watts TH. Staying alive: T cell costimulation, CD28, and Bcl-xL. J Immunol. 2010;185(7): 3785-3787.
34. Waldmann H. Tolerance: An overview and perspectives. Nat Rev Nephrol. 2010;6(10): 569-576.
35. Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005; 307(5712):1101-1104.
36. Tomita Y, Sachs DH, Sykes M. Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood. 1994; 83(4):939-948.
37. Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science. 2007;318(5854):1296-1299.
38. Fujisaki J, Wu J, Carlson AL, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature. 2011; 474(7350):216-219.
39. Bhattacharya D, Czechowicz A, Ooi AG, Rossi DJ, Bryder D, Weissman IL. Niche recycling through division-independent egress of hematopoietic stem cells. J Exp Med. 2009; 206(12):2837-2850.
40. Muller-Sieburg CE, Cho RH, Karlsson L, Huang JF, Sieburg HB. Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. Blood. 2004; 103(11):4111-4118.
41. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell. 2010;6(3):265-278.
42. Sachs DH, Sykes M, Kawai T, Cosimi AB. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol. 2011;23(3):165-173.
43. Page A, Srinivasan S, Singh K, et al. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant. 2012;12(1):115-125.
44. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
45. Kraus AK, Cippá PE, Gaspert A, et al. Absence of donor CD40 protects renal allograft epithelium and preserves renal function. Transpl Int. 2013; 26(5):535-544.
46. Goldwater R, Keirns J, Blahunka P, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant. 2013;13(4): 1040-1046.
47. Pilat N, Baranyi U, Klaus C, et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant. 2010;10(4):751-762.